The year 2026 has crowned one peptide as the undisputed champion of metabolic health, body recomposition and type-2 diabetes management: Tirzepatide – the groundbreaking dual GLP-1/GIP receptor agonist that has consistently outperformed every previous compound in clinical trials, delivering average weight loss of 22–25 % and HbA1c reductions of 2.3–2.8 %. When licensed physicians, private […]